On August 30, 2018 Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company that develops antibody-based drug candidates for tumor-directed immunotherapy, reported that the company will participate as a presentation company at the investor conference of the 20th Annual Rodman & Renshaw Global Investment Conference, a joint venture with HC Wainwright & Co., LLC (Press release, Alligator Bioscience, AUG 30, 2018, https://alligatorbioscience.se/alligator-bioscience-presenterar-pa-20th-annual-rodman-renshaw-global-investment-conference/ [SID1234529415]). The conference will take place on 4-6 September on St. Regis New York Hotel in New York, USA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
CEO Per Norlén will provide a status overview of the company during the company presentation and also participate in individual meetings with investors registered at the conference.
Event: Corporate Presentation at 20th Annual Rodman & Renshaw Global Investment Conference
Date: September 6, 2018
Time: at. 21.25-21.50 CEST (15.25-15.50 local time)
Location: Library (2nd floor); the st. Regis New York Hotel in New York City, USA
The presentation will be live live. To listen to the presentation, please use the following direct link: View Source or visit View Source . The webcast is available for 90 days after the presentation.
For further information please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Telephone: 046-286 44 95
Email: [email protected]